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An unexpected twist to the activation of IKKβ: TAK1 primes IKKβ for
activation by autophosphorylation
Jiazhen ZHANG*, Kristopher CLARK*, Toby LAWRENCE†, Mark W. PEGGIE* and Philip COHEN*1
*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
†Centre d’Immunologie de Marseille-Luminy, Parc Scientifique & Technologique de Luminy, Case 906, 13288 Marseille cedex 09, France
IKKβ {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase
β} is required to activate the transcription factor NF-κB, but
how IKKβ itself is activated in vivo is still unclear. It was
found to require phosphorylation by one or more ‘upstream’
protein kinases in some reports, but by autophosphorylation
in others. In the present study, we resolve this contro-
versy by demonstrating that the activation of IKKβ induced
by IL-1 (interleukin-1) or TNF (tumour necrosis factor) in
embryonic fibroblasts, or by ligands that activate Toll-like
receptors in macrophages, requires two distinct phosphorylation
events: first, the TAK1 [TGFβ (transforming growth factor
β)-activated kinase-1]-catalysed phosphorylation of Ser177 and,
secondly, the IKKβ-catalysed autophosphorylation of Ser181.
The phosphorylation of Ser177 by TAK1 is a priming event
required for the subsequent autophosphorylation of Ser181, which
enables IKKβ to phosphorylate exogenous substrates. We also
provide genetic evidence which indicates that the IL-1-stimulated,
LUBAC (linear ubiquitin chain assembly complex)-catalysed
formation of linear ubiquitin chains and their interaction with
the NEMO (NF-κB essential modulator) component of the
canonical IKK complex permits the TAK1-catalysed priming
phosphorylation of IKKβ at Ser177 and IKKα at Ser176. These
findings may be of general significance for the activation of other
protein kinases.
Key words: inhibitor of nuclear factor κB kinase (IKK),
interleukin-1 (IL-1), linear ubiquitin chain assembly complex
(LUBAC), nuclear factor κB (NF-κB), transforming growth factor
β-activated kinase-1 (TAK1).
INTRODUCTION
The canonical IKK {IκB [inhibitor of NF-κB (nuclear factor κB)]
kinase β} complex, consisting of the protein kinases IKKα and
IKKβ (also called IKK1 and IKK2) and a regulatory component
called NEMO (NF-κB essential modifier) [1,2], is one of the
most studied of all protein kinases. It has featured in over 10000
papers since its discovery in 1998 due to its essential role in
activating NF-κB, a ‘master’ transcription factor that regulates
many physiological processes, including innate immunity and the
cellular response to DNA damage [3–5]. Nevertheless, despite
the vast number of publications that have focused on this protein
kinase, its mechanism of activation is still controversial.
The activation of IKKα and IKKβ requires phosphorylation of
the ‘activation loops’ of these protein kinases at Ser176 and Ser180
(IKKα) or Ser177 and Ser181 (IKKβ) [4]. The IKKs respond to
many physiological stimuli, but are activated most powerfully by
inflammatory stimuli, such as TLR (Toll-like receptor) agonists
and the pro-inflammatory cytokines IL-1 (interleukin-1) and TNF
(tumour necrosis factor). Genetic evidence indicates that the
expression and activity of the TAK1 [TGFβ (transforming growth
factor β)-activated kinase-1; also called MAP3K7 (mitogen-
activated protein kinase kinase kinase 7)] is needed for the
activation of the canonical IKK complex by IL-1 and TNF
in MEFs (mouse embryonic fibroblasts). These agonists fail to
activate the IKKs in MEFs that do not express the TAK1 catalytic
subunit [6] or that express a truncated inactive form of TAK1 [7].
IL-1 and TNF trigger TAK1 activation within minutes, a speed
compatible with a role in initiating the activation of the IKKs [8].
TAK1 is also reported to phosphorylate and activate the canonical
IKKs in vitro [9], activation being prevented by pharmacological
inhibitors of TAK1 [8,10,11]. Similar lines of evidence indicate an
essential role for TAK1 in activating the MKKs [MAPK (mitogen-
activated protein kinase) kinases] that switch on the MAPK family
members JNK1 (c-Jun N-terminal kinase 1) and JNK2 and p38
MAPKs in MEFs [8–11].
On the other hand, the canonical IKKs have been shown
to be capable of phosphorylating and activating themselves
in vitro (reviewed in [4]). For example, Met1-linked (also called
linear) ubiquitin oligomers [12] and other types of ubiquitin
oligomers [13] have been reported to induce the activation of the
canonical IKK complex in vitro, apparently in the absence of
any ‘upstream’ activating protein kinase. These observations raise
the alternative possibility that the role of TAK1 in vivo might be
to stimulate the formation of these polyubiquitin chains, rather
than to phosphorylate the canonical IKK complex directly. In
addition, X-ray crystallographic analysis has revealed that human
IKKβ can adopt an open conformation that enables it to form
oligomers, whereas mutagenesis studies have established that two
of the surfaces that mediate oligomer formation are critical for the
activation of IKKβ in cells [14]. It has therefore been proposed
that IKKβ dimers transiently associate with one another through
these interaction surfaces to promote trans autophosphorylation as
part of their activation mechanism. Consistent with an essential
Abbreviations: BMDM, bone-marrow-derived macrophage; E, embryonic day; HA, haemaglutinnin; HEK, human embryonic kidney; HOIP, HOIL1
[haem-oxidized IRP2 (iron regulatory protein 2) ubiquitin ligase 1]-interacting protein; IκB, inhibitor of NF-κB; IKK, IκB kinase; IL-1, interleukin-1; JNK,
c-Jun N-terminal kinase; LPS, lipopolysaccharide; LUBAC, linear ubiquitin chain assembly complex; MAPK, mitogen-activated protein kinase; M-CSF,
macrophage colony-stimulating factor; MEF, mouse embryonic fibroblast; MKK, MAPK kinase; NEMO, NF-κB essential modulator; NF-κB, nuclear factor
κB; PP1γ, protein phosphatase 1γ; TAB, TAK1-binding protein; TAK1, transforming growth factor β-activated kinase-1; TLR, Toll-like receptor; TNF, tumour
necrosis factor; TRAF, TNF receptor-associated factor.
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role for autophosphorylation, we found that in IKKα-deficient
MEFs the specific IKKβ inhibitor BI605906 prevented the IL-
1- or TNF-stimulated conversion of IKKβ into the active di-
phosphorylated species, i.e. phosphorylated at both Ser177 and
Ser181 [8].
In the present study we report the unexpected finding that
TAK1 and IKKβ phosphorylate different serine residues in the
activation loop of IKKβ and demonstrate that the TAK1-catalysed
phosphorylation of IKKβ at Ser177 is a priming event that enables
IKKβ to activate itself by phosphorylating Ser181. We also provide
genetic evidence showing that the formation of Met1-linked
ubiquitin chains and their interaction with NEMO is needed for
the TAK1-catalysed phosphorylation of Ser176 (IKKα) and Ser177
(IKKβ), and that TAK1 activity is not required for the formation
of either Lys63-linked or Met1-linked ubiquitin chains.
EXPERIMENTAL
Materials
Murine IL-1α and TNF were purchased from Peprotech and
mouse M-CSF (macrophage colony-stimulating factor) from
R&D Systems. Pam3CSK4 was from Invivogen and LPS
(lipopolysaccharide) O55:B5 was from Enzo Life Science.
The monophosphorylated peptide KELDQGpSLCTSFVGTLQ
and the diphosphorylated peptide KELDQGpSLCTpSFVGTLQ
(where pS is phosphoserine), corresponding to amino acids 171–
187 of IKKβ with phosphoserine at Ser177 only or at both Ser177
and Ser181 respectively, were synthesized by Pepceuticals. The
IKKβ inhibitor BI605906 [8] was provided by Dr Natalia Shpiro
(University of Dundee, Dundee, U.K.) and the TAK1 inhibitor
NG25 by Dr Nathanael Gray (Harvard Medical School, Boston,
MA, U.S.A.) [11], whereas the TAK1 inhibitor 5Z-7-oxozeaenol
was purchased from BioAustralis Fine Chemicals.
Protein expression and purification
The IKKβ (IKKβ[D166A]) was expressed as a GST fusion
protein in HEK (human embryonic kidney)-293T suspension
cells and, after cell lysis, was purified from the cell extracts
by chromatography on glutathione–Sepharose. The GST-fusion
protein was released from the glutathione–Sepharose by cleavage
of the GST tag with PreScission protease. A catalytically active
TAK1–TAB1 (TAK1-binding protein 1)-fusion protein [15] was
expressed in insect Sf21 cells as a His6-tagged protein and
purified by chromatography on nickel-nitrilotriacetate agarose.
The catalytic subunit of human PP1γ (protein phosphatase 1γ )
was expressed in Escherichia coli as a GST-fusion protein,
purified on glutathione–Sepharose and stored in a solution of
50 mM Tris/HCl, 0.15 M NaCl, 0.27 M sucrose, 0.03% Brij35,
0.1% 2-mercaptoethanol and 2 mM MnCl2.
Antibodies
An antibody recognizing the HOIP {HOIL1 [haem-oxidized IRP2
(iron regulatory protein 2) ubiquitin ligase 1]-interacting protein}
component of LUBAC (linear ubiquitin chain assembly complex)
was raised in sheep and purified as described in [16]. Antibodies
recognizing IKKβ phosphorylated at Ser177 (catalogue number
2078S) or at both Ser177 and Ser181 (catalogue number 2697L)
were obtained from Cell Signaling Technology, whereas the
antibody recognizing IKKβ phosphorylated at Ser181 was from
Abcam (catalogue number AB55341). Antibodies that recognize
p105/NF-κB1 phosphorylated at Ser933 (catalogue number
4806S), GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
catalogue number 2118S) and all forms of p38α MAPK
(catalogue number 9212S) and JNK (catalogue number 9258S)
were from Cell Signaling Technology. Antibodies recognizing
NEMO (catalogue number SC8330; Santa Cruz Biotechnology),
all forms of IKKβ (catalogue number DAM1774677; Millipore)
and the HA (haemaglutinnin) tag (catalogue number 12-013-
819-001; Roche) were from the sources indicated. An antibody
raised in sheep against the full-length human IKKβ catalytic
subunit (S189C, bleed 1) was produced and affinity purified by the
Antibody Production Team of the MRC Protein Phosphorylation
and Ubiquitylation Unit at Dundee (co-ordinated by Dr James
Hastie). An antibody recognizing Met1-linked ubiquitin chains
was generously provided by Vishva Dixit, Genentech, U.S.A.
and the antibody recognizing Lys63-linked ubiquitin chains was
purchased from Merck-Millipore (catalogue number 05-1313).
DNA constructs
DNA encoding IKKβ (NCBI BAI45894.1) was amplified
from total thymus RNA using the One Step RT PCR kit
(Life Technologies). It was then cloned into pCR2.1 (Life
Technologies), sequenced and sub-cloned into the Not1 site
of pRetrox tight HA. Mutations were created following the
QuikChange Site-Directed Mutagenesis method, but using KOD
Hot Start DNA Polymerase (EMD Millipore).
Cell culture, stimulation and immunoblotting
MEFs and HEK-293 cells were maintained in DMEM
(Dulbecco’s modified Eagle’s medium) supplemented with 2 mM
glutamine, 10% (v/v) FBS, and the antibiotics streptomycin
(0.1 mg/ml) and penicillin (100 units/ml). DNA constructs
were transfected into HEK-293 cells using polyethyleneimine
(Polysciences). BMDMs (bone-marrow-derived macrophages)
were obtained by culturing bone marrow from the tibia and
femurs of mice in the presence of mouse M-CSF and replating
for 24 h before stimulation. Kinase inhibitors (10 mM) dissolved
in DMSO, or an equivalent volume of DMSO for the control
incubations, were added to the culture medium of cells grown
as monolayers. After 1 h at 37 ◦C, MEFs were stimulated with
IL-1α or TNF and BMDM with LPS or Pam3Csk4 (see the
Figure legends). Thereafter, cells were rinsed in ice-cold PBS and
extracted in lysis buffer [50 mM Tris/HCl (pH 7.4), 1 mM EDTA,
1 mM EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM
sodium 2-glycerol 1-phosphate, 1 mM DTT, 1 mM sodium
orthovanadate, 0.27 M sucrose, 1% (v/v) Triton X-100, 1 μg/ml
aprotinin, 1 μg/ml leupeptin and 1 mM PMSF]. Cell extracts
were clarified by centrifugation (21000 g for 10 min at 4 ◦C)
and protein concentrations determined by the Bradford assay.
Cell extract protein (20 μg) was separated by SDS/PAGE (8%
gel), transferred on to PVDF membranes and proteins detected
by immunoblotting and visualized by treating the blots with
enhanced chemiluminescence (Amersham).
Generation of MEFs from knockin mice
Mice in which wild-type NEMO was replaced by the
polyubiquitin-binding-defective mutant NEMO[D311N] were
generated by Taconic-Artemis using conventional technology
and their characterization will be reported elsewhere. Primary
MEFs from NEMO[D311N] mice and wild-type littermates were
generated at E11.5 (embryonic day 11.5), whereas MEFs from
knockin mice expressing the inactive C879S mutant of HOIP were
generated at E10.5 [16]. Immortalized IKKα-deficient MEFs and
wild-type control MEFs were provided by Dr Inder Verma (Salk
Institute, La Jolla, CA, U.S.A.). All animals were maintained in
specific pathogen-free conditions consistent with EU and U.K.
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Figure 1 Effect of protein kinase inhibitors on the phosphorylation of IKKβ at Ser177 and/or Ser181 in MEFs from IKKα-deficient mice and BMDMs from knockin
mice expressing catalytically inactive IKKα[S176A/S180A]
(A) MEFs from IKKα-knockout mice were incubated for 1 h without ( − ) or with ( + ) 1.0 μM NG25, 1.0 μM 5Z-7-oxozeaenol or 5.0 μM BI605906, then stimulated for 10 min with 5.0 ng/ml IL-1.
Cell lysates were subjected to SDS/PAGE and immunoblotting as described in the Experimental section. (B) The experiment was performed exactly as in (A) except that the cells were stimulated
with 10 ng/ml TNF. (C and D) BMDMs from knockin mice expressing the catalytically inactive IKKα[S176A/S180A] mutant were incubated for 1 h without ( − ) or with ( + ) 2 μM NG25 or 2 μM
BI605906, then stimulated for 10 min with 1 μg/ml Pam3CSK4 (C) or 0.1 μg/ml LPS (D). Cell extracts were subjected to SDS/PAGE and immunoblotted as in (A and B).
regulations. All work was performed under a U.K. Home Office
project license that was awarded after recommendation by the
University of Dundee Ethical Review Committee.
Retroviral transduction of IKKα-knockout MEFs
IKKα-deficient MEFs stably expressing HA-tagged empty vector
(EV), wild-type HA–IKKβ (WT), HA–IKKβ[S177A], HA–
IKKβ[S177E] or HA–IKKβ[D166A/S177E] were generated
by retroviral transduction using an MMLV (Moloney
murine leukaemia virus)-based system prepared with the
VSVG (vesicular-stomatitis-virus glycoprotein) envelope protein.
Retroviral particles were prepared according to the manufacturer’s
instructions (Clontech). Viruses encoding the gene of interest and
the Tet-On protein were harvested 48 h after transfection, diluted
4-fold with fresh medium and incubated for 24 h with IKKα-
deficient MEFs in the presence of 2 μg/ml protamine sulfate
(Sigma). Fresh medium containing 1 μg/ml G418 (Tet-On) and
3 μg/ml puromycin (gene of interest) was added to select the
transduced cells. Cells were cultured for 16 h with doxycycline
(0.1–1.0 μg/ml) to induce the expression of wild-type and mutant
forms of IKKβ.
Immunoprecipitation and dephosphorylation of IKKβ
To immunoprecipitate transfected HA-tagged IKKβ, cell extract
protein (40 μg) was incubated for 60 min at 4 ◦C with 4 μg of
anti-HA antibody, whereas for the endogenous IKKβ 0.2 mg
of cell extract protein was incubated with 2.5 μg of anti-IKKβ
antibody. Protein G–Sepharose was added (equivalent to 10 μl
packed volume) and, after mixing for 30 min at 4 ◦C, immune
complexes were collected by brief centrifugation, washed three
times in cell lysis buffer plus 0.5 M NaCl, and three times
with 50 mM Tris/HCl (pH 7.5), 0.05 M NaCl and 1.0 mM DTT,
then resuspended in 0.03 ml of 50 mM Hepes, 10 mM NaCl,
2 mM DTT and 0.1% Brij35 (pH 7.5) containing 1 mM MnCl2.
Dephosphorylation was initiated by the addition of 100 μg
of GST–PP1γ . After 60 min at 30 ◦C the immunoprecipitates
were collected, washed three times with 1.0 ml of lysis buffer
containing 0.5 M NaCl, and three times with 50 mM Tris/HCl
(pH 7.5), 0.1 mM EGTA and 0.1% 2-mercaptoethanol to remove
the phosphatase.
Assay of immunoprecipitated IKKβ
IKKβ immunoprecipitates were assayed for IKKβ activity in a
0.05 ml incubation containing 50 mM Tris/HCl (pH 7.5), 0.1 mM
EGTA and 0.1% 2-mercaptoethanol, 1.0 μM microcystin (to
inactivate any remaining traces of PP1γ ), 0.3 mM of the
peptide LDDRHDSGLDSMKDEEY (corresponding to amino
acid residues 26–42 of IκBα), 10 mM magnesium acetate and
0.1 mM [γ 32P]ATP (5×105 c.p.m./nmol). After incubation for
10 min at 30 ◦C on a shaking platform, the incorporation of 32P
radioactivity into the peptide substrate was measured as described
in [17].
RESULTS
IKKβ is activated by TAK1 and by autophosphorylation
We initially confirmed that IL-1 or TNF stimulate the dual
phosphorylation of IKKβ at Ser177 and Ser181 in IKKα-deficient
MEFs, and that this was prevented by the inclusion of the
IKKβ inhibitor BI605906 in the culture medium (Figures 1A
and 1B, top panel, compare lanes 1–3 with 10–12). In these
and many earlier studies, the phospho-specific antibody used
to monitor the phosphorylation of IKKβ recognizes the di-
phosphorylated species phosphorylated at both Ser177 and Ser181.
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It was therefore possible that BI605906 and/or pharmacological
inhibitors of TAK1 had suppressed the phosphorylation of just
one of the serine residues in the activation loop. To address this
possibility we therefore employed antibodies that recognize IKKβ
phosphorylated at either Ser177 or Ser181. These studies led to
the striking and surprising observation that BI605906 suppressed
the IL-1- or TNF-stimulated phosphorylation of Ser181, but not
the phosphorylation of Ser177 (Figures 1A and 1B, second and
third panels from top, lanes 10–12). In contrast, two structurally
unrelated inhibitors of TAK1, NG25 and 5Z-7-oxozeaenol,
prevented IL-1 or TNF from inducing the phosphorylation
of IKKβ at both Ser177 and Ser181 in IKKα-deficient MEFs
(Figures 1A and 1B, second and third lanes from top, lanes
4–9). Similar results were observed in BMDMs from knockin
mice expressing the catalytically inactive IKKα[S176A/S180A]
mutant (Figures 1C and 1D) [18].
The recognition of IKKβ by the Ser177 phospho-specific
antibody appeared to be greatly enhanced when IKKα-deficient
MEFs were incubated with BI605906 and then stimulated
with IL-1 or TNF (Figures 1A and 1B, second panel from
top, compare lanes 10–12 with 1–3). This observation is
explained by the failure of the antibody to recognize IKKβ
phosphorylated at Ser177 if Ser181 is also phosphorylated, and
is not a reflection of a real increase in the phosphorylation
of Ser177. This was shown by immunoblotting experiments
with a synthetic mono-phosphorylated peptide corresponding
to amino acid residues 171–187 of IKKβ containing phospho-
serine at the position equivalent to Ser177, and a diphosphorylated
form of this peptide with phosphoserine present at both
Ser177 and Ser181 (Supplementary Figures S1A and S1B at
http://www.biochemj.org/bj/461/bj4610531add.htm). We have
encountered similar situations with other proteins in which
the two sites of phosphorylation are separated by only four
amino acid residues (e.g. [19]). In contrast, the antibody that
recognizes the Ser181-phosphorylated form of IKKβ detected the
di-phosphorylated form of the peptide (Supplementary Figure
S1C), because this antibody recognizes the epitope Cys-Thr-pSer-
Phe-Val (where pSer is phospho-Ser181), which does not contain
Ser177. As expected, the antibody recognizing Ser181 of IKKβ did
not detect the mono-phosphorylated peptide containing phospho-
serine only at Ser177 (Supplementary Figure S1C).
The simplest interpretation of the results presented in
Figure 1 was that the TAK1-catalysed phosphorylation of
Ser177 was a prerequisite for the subsequent IKKβ-catalysed
phosphorylation of Ser181. To investigate this hypothesis, we
generated IKKα-deficient MEFs that stably expressed (under an
inducible promoter) mutated forms of IKKβ in which Ser177
was changed to either glutamic acid (to mimic the effect
of phosphorylation by introducing a negative charge) or to
alanine (to prevent phosphorylation). The S177E mutant became
phosphorylated at Ser181, even in MEFs that had not been
stimulated with IL-1 or TNF, whereas the S177A mutant or
wild-type IKKβ did not (Figure 2A). Moreover, under these
conditions, incubation with the IKKβ inhibitor BI605906 induced
substantial dephosphorylation of the S177E mutant at Ser181,
whereas incubation with the TAK1 inhibitor NG25 had no effect.
Furthermore, a catalytically inactive version of the S177E mutant,
created by additionally mutating Asp166 in the Asp-Phe-Gly
motif to alanine, failed to undergo phosphorylation at Ser181
(Figure 2B). Taken together, these experiments demonstrated,
by two independent methods, that the phospho-mimetic S177E
mutation permits IKKβ to autophosphorylate Ser181.
IKKβ initiates the activation of NF-κB in vivo by phosphorylat-
ing the inhibitory IκBα component at Ser32 and Ser36. The
IKKβ[S177E]-catalysed phosphorylation of a synthetic peptide
Figure 2 Expression of IKKβ[S177E] induces the autophosphorylation of
Ser181 and activation of IKKβ
(A) MEFs from IKKα-deficient mice stably expressing HA-tagged wild-type IKKβ (WT),
IKKβ[S177E] (S177E) or IKKβ[S177A] (S177A) or empty vector (EV) were incubated for
16 h with 1.0 μg/ml (WT and EV), 0.2 μg/ml (S177A) or 0.1 μg/ml (S177E) doxycycline to
induce the expression of these proteins, and then for 1 h without ( − ) or with ( + ) 5 μM
NG25 or 5 μM BI605906 and lysed. Extract [20 μg (EV, S177E and S177A) or 80 μg (WT)
protein] were analysed by immunoblotting with the antibodies indicated. (B) As in (A), except
that Ser181 phosphorylation was studied in MEFs stably expressing HA–IKKβ[D166A/S177E]
and HA–IKKβ[S177E], and no inhibitors were present. (C and D) HA-tagged IKKβ[S177E] was
transfected into HEK-293 cells, immunoprecipitated from the cell extracts, incubated without
( − ) or with ( + ) PP1γ and assayed for IKKβ activity (C) or immunoblotted with antibodies
that recognize IKKβ phosphorylated at Ser181 or all forms of IKKβ (D). The results in (C)
are means+−S.E.M. of duplicate determinations. Similar results were obtained in two other
independent experiments.
comprising amino acid residues 26–42 of IκBα was suppressed
by BI605906 similarly to wild-type IKKβ (Supplementary Fig-
ures S2 at http://www.biochemj.org/bj/461/bj4610531add.htm),
establishing that the activity being measured was catalysed
by IKKβ and not by another protein kinase present in the
immunoprecipitates as a contaminant. Phosphatase treatment
inactivated the IKKβ[S177E] mutant (Figure 2C), and this was
accompanied by the dephosphorylation of Ser181 and a small
increase in the electrophoretic mobility of IKKβ (Figure 2D).
These experiments established that the phospho-mimetic S177E
mutation had not activated IKKβ, but permitted IKKβ to auto-
activate by phosphorylating Ser181.
BI605906 is a reversible inhibitor of IKKβ (Sup-
plementary Figure S3 at http://www.biochemj.org/bj/461/
bj4610531add.htm). To investigate whether the phosphorylation
of Ser177 could activate IKKβ in the absence of Ser181
phosphorylation, we incubated IKKα-deficient MEFs with
BI605906 to supress the phosphorylation of Ser181 and assayed the
endogenous IKKβ activity after its immunoprecipitation from the
extracts of IL-1-stimulated cells. These experiments showed that
IKKβ mainly phosphorylated at Ser177 had a much lower activity
than IKKβ phosphorylated at both Ser177 and Ser181 (Figure 3A).
Taken together, the results presented in Figures 2 and 3 indicate
that Ser177 is a priming event that enables IKKβ to auto-activate
itself by phosphorylating Ser181.
Activation of the canonical IKK complex
The experiments presented above were carried out in IKKα-
deficient MEFs or in BMDMs from knockin mice expressing
the catalytically inactive IKKα[S176A/S180A] mutant, because
IKKα activity is unaffected by BI605906 [8]. In contrast, the
c© The Authors Journal compilation c© 2014 Biochemical Society
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Figure 3 IKKβ phosphorylated at Ser177 has little activity if Ser181 is not phosphorylated
(A) MEFs from IKKα-deficient mice were incubated for 1 h without ( − ) or with ( + ) 5.0 μM BI 605906 or 2 μM NG25, then stimulated for 10 min with 5.0 ng/ml IL-1. The endogenous IKKβ was
immunoprecipitated from 0.2 mg of cell extract protein and assayed for activity. (B) The immunoprecipitates from (A) were denatured in SDS before and after the assay of IKKβ , and aliquots of each
sample were subjected to SDS/PAGE, transferred on to PVDF membranes and immunoblotted with antibodies that recognize IKKβ phosphorylated at Ser177 or Ser181 or all forms of IKKβ .
phosphorylation of IKKβ at Ser181 was only decreased slightly
by BI605906 in wild-type MEFs (Supplementary Figures S4A
and S4B at http://www.biochemj.org/bj/461/bj4610531add.htm)
and was not decreased significantly in Pam3CSK4- or
LPS-stimulated BMDMs (Supplementary Figures S4C). This
suggests that in wild-type cells, in which IKKα, IKKβ and
NEMO form a single ternary complex, phosphorylation of IKKβ
at Ser181 can be catalysed in trans by IKKα if IKKβ is inhibited
by BI605906.
The formation of Met1-linked ubiquitin chains and their interaction
with NEMO is required for TAK1 to phosphorylate IKKα and IKKβ at
Ser176/Ser177
LUBAC is the only E3 ubiquitin ligase that catalyses the formation
of Met1-linked (linear) ubiquitin chains in IL-1-stimulated MEFs,
and the formation of these ubiquitin chains is required for robust
activation of the canonical IKK complex by this agonist ([16],
reviewed in [3]). To investigate whether Met1-linked ubiquitin
chain formation was required for the phosphorylation of Ser177,
Ser181 or both amino acid residues, we studied the phosphorylation
of each of these sites in MEFs from knockin mice in which HOIP,
the catalytic subunit of LUBAC, was replaced by the inactive
HOIP[C879S] mutant [16]. These experiments demonstrated
that the IL-1-stimulated phosphorylation of IKKβ at Ser177 or
Ser181 or IKKα at Ser176 or Ser180 was greatly reduced in MEFs
from HOIP[C879S]-knockin mice, as was the phosphorylation of
p105/NFκB1 at Ser933, an established physiological substrate of
IKKβ (Figure 4A) [20].
The Met1-linked ubiquitin chains formed by LUBAC bind to
the NEMO component of the canonical IKK complex (reviewed
in [3]). We therefore generated knockin mice expressing
NEMO[D311N], an ubiquitin-binding-defective mutant of
NEMO [21–23], and studied the phosphorylation of IKKβ in
MEFs from these animals. We found that the IL-1-stimulated
Figure 4 Met1-linked ubiquitin chains and their interaction with NEMO are
required for the IL-1-stimulated phosphorylation of IKKα and IKKβ in MEFs
(A) Cells from wild-type (HOIP[WT]) or knockin mice expressing the HOIP[C879S] mutant were
stimulated with 5 ng/ml IL-1 for the times indicated and lysed. The extract (20 μg of protein)
was subjected to immunoblotting and probed with the antibodies indicated. (B) As in (A) except
that MEFs from NEMO[D311N]-knockin and wild-type mice were used.
phosphorylation of IKKβ at Ser177 or Ser181, or IKKα at Ser176
or Ser180, was impaired in MEFs expressing the NEMO[D311N]
mutant (Figure 4B), similar to the results obtained in MEFs from
the HOIP[C879S]-knockin mice (Figure 4A).
c© The Authors Journal compilation c© 2014 Biochemical Society
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The IL-1-stimulated phosphorylation of JNK1/JNK2 and p38α
MAPK in MEFs from HOIP[C879S] or NEMO[D311N] mice
was similar to wild-type MEFs (Supplementary Figure S5 at
http://www.biochemj.org/bj/461/bj4610531add.htm), but was
suppressed by the TAK1 inhibitors NG25 or 5Z-7-oxozeaenol
(Supplementary Figure S6 at http://www.biochemj.org/
bj/461/bj4610531add.htm). These control experiments indicated
that activation of the TAK1 complex was unimpaired in
MEFs from HOIP[C879S]- or NEMO[D311N]-knockin
mice. The TAK1 inhibitor NG25 did not affect the IL-
1-stimulated formation of Lys63-linked ubiquitin chains
significantly and actually enhanced Met1-linked ubiquitin chain
production in IKKα-deficient MEFs (Supplementary Figure S7
at http://www.biochemj.org/bj/461/bj4610531add.htm). Thus
TAK1 activity is not required for the IL-1-stimulated formation of
Lys63-linked or Met1-linked ubiquitin chains and NG25 does not
suppress the phosphorylation of IKKβ by preventing formation
of the ubiquitin chains. The enhanced formation of Met1-linked
ubiquitin chains in the presence of NG25 implies the existence of
a TAK1-dependent feedback control mechanism for restricting
the formation of these ubiquitin chains.
Finally, it should be noted that although TAK1 phosphorylates
the IKKβ–NEMO complex at Ser177 in IKKα-deficient
MEFs, the active TAK1 catalytic subunit is capable of phos-
phorylating a catalytically inactive mutant of the IKKβ catalytic
subunit at Ser181, as well as Ser177, in vitro (Supplementary Figure
S8 at http://www.biochemj.org/bj/461/bj4610531add.htm). It is
therefore possible that the interaction of NEMO with IKKβ in
the canonical IKK complex and/or the recruitment of the TAK1
complex to Lys63-linked ubiquitin chains are factors that prevent
TAK1 from phosphorylating Ser181 in cells.
DISCUSSION
In the present study, we have clarified the mechanism by which
the canonical IKK complex is activated. Unexpectedly, we
discovered that the activation of IKKβ requires two sequential
phosphorylation events. The activation process is initiated by the
TAK1-catalysed phosphorylation of IKKβ at Ser177, which is a
priming event that permits IKKβ to phosphorylate itself at Ser181,
which is needed before IKKβ can phosphorylate exogenous
substrates, such as IκBα (Figure 5). We have shown that this
mechanism of activation operates in IL-1- or TNF-stimulated
MEFs and in TLR-stimulated BMDMs indicating that is likely to
be of general significance. However, the identity of the ‘priming’
kinase may vary from cell to cell.
The mutation of Ser177 of IKKβ to glutamic acid (to mimic
the effect of phosphorylation by introducing a negative charge)
permitted the IKKβ catalytic subunit to autophosphorylate at
Ser181 and this induced activation even in cells that had not been
stimulated with IL-1 or TNF. Interestingly, the other two members
of the IKK subfamily of protein kinases, IKKε and TBK1
{TANK [TRAF (TNF receptor-associated factor)-associated NF-
κB activator]-binding kinase 1}, both possess a glutamic acid
at position 168 in their activation loops, which is the amino
acid residue equivalent to Ser176/Ser177 of IKKα/β, and they are
activated by the phosphorylation of Ser172, the site equivalent
to Ser180/Ser181 of IKKα/IKKβ [8]. These features explain why
these IKK-related kinases are not activated directly by TAK1
in vivo and why they are instead activated by the canonical IKK
complex and by autophosphorylation in response to IL-1 [8]. Once
activated, IKK-related kinases restrict the activity of the canonical
IKKs by phosphorylating inhibitory sites on the canonical IKKs,
Figure 5 Proposed mechanism for the activation of IKKβ by IL-1 in IKKα-
deficient MEFs
IL-1 stimulates the formation of hybrid ubiquitin chains in which LUBAC-generated Met1-linked
ubiquitin oligomers are attached covalently to TRAF6-generated Lys63-linked ubiquitin
oligomers. The binding of Lys63-linked ubiquitin to TAB2 or TAB3 activates the TAK1 complex
by inducing autophosphorylation of the catalytic subunit at Thr187 [31]. The M1-linked ubiquitin
chains interact with NEMO permitting TAK1 to phosphorylate IKKβ at Ser177. Phosphorylation of
Ser177 allows autophosphorylation of Ser181. The activated IKKβ can then phosphorylate IκBα.
Sites of phosphorylation are denoted by ‘P’.
which is critical to prevent autoimmune nephritis in mice
[8,24].
The activation of the canonical IKK complex by IL-1 does
not just require the phosphorylation of serine residues in the
activation loop, but also the formation of a hybrid ubiquitin
chain containing both Lys63-linked and Met1-linked ubiquitin
oligomers [16]. The Lys63-linked ubiquitin chains interact with
the TAB2 and TAB3 components of TAK1 complexes, in-
ducing the auto-activation of TAK1 [9,13,25], whereas the Met1-
linked ubiquitin chains formed by the action of the E3 ubiquitin
ligase LUBAC [16,26] interact with NEMO [27,28] and are
critical for activation of the canonical IKK complex [12,16,29].
Nearly all of the Met1-linked ubiquitin chains formed in response
to IL-1 are attached covalently to Lys63-linked ubiquitin chains,
which may facilitate the TAK1-dependent activation of canonical
IKK complex by recruiting both protein kinases to the same
ubiquitin chains [16]. In the present study, we found that the
IL-1-stimulated phosphorylation of IKKα/IKKβ at Ser176/Ser177,
and hence the phosphorylation of Ser180/Ser181, was suppressed
in MEFs that were unable to produce Met1-linked ubiquitin
chains or that expressed a ubiquitin-binding-defective mutant of
NEMO (Figure 4). Thus the formation of Met1-linked ubiquitin
chains and their interaction with NEMO are both needed for
TAK1 to phosphorylate IKKα/IKKβ at Ser176/Ser177 and so enable
the IKKs to complete the activation process by phosphorylating
Ser180/Ser181 (Figure 5).
The activation of many protein kinases requires the
phosphorylation of two amino acid residues within their activation
loops. For example, similar to the canonical IKK complex, the
seven members of the MKK family undergo dual phosphorylation
at Ser/Thr-Xaa-Xaa-Xaa-Ser/Thr (where Xaa is any amino acid
residue) sequences, enabling them to activate their cognate
MAPKs. Similarly, most MAPKs are activated by the dual
phosphorylation of a threonine and a tyrosine residue that are
located in Thr-Xaa-Tyr within their activation loops. Although the
activation of many MKKs and MAPKs is thought to be catalysed
by a single protein kinase, the present study has shown that the
requirement for one ‘upstream’ protein kinase does not exclude
the possibility that a second protein kinase is also required.
Indeed, we have shown that the activation of JNK requires
the MKK7-catalysed phosphorylation of the threonine and the
MKK4-catalysed phosphorylation of the tyrosine residue within
c© The Authors Journal compilation c© 2014 Biochemical Society
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the Thr-Xaa-Tyr motif [30]. The activation of a kinase by two
different ‘upstream’ kinases provides additional opportunities for
signal integration if each activating kinase responds to distinct
physiological cues. We suggest that this situation may be a more
frequent occurrence than has hitherto been realized, and that this
is a neglected area that merits further attention.
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Figure S1 Phosphorylation of Ser181 interferes with the recognition of
phosphor-Ser177 by the phospho-specific antibody that recognizes this site
(A) The indicated amounts of phosphopeptides corresponding to amino acid residues 171–187 of
IKKβ phosphorylated at Ser177 only or at both Ser177 and Ser181 were spotted on to nitrocellulose
membranes and probed with the phospho-specific antibody recognizing phospho(p)-Ser177. (B)
Same as (A), except that the peptides were immunoblotted with the antibody that only recognizes
the di-phosphorylated form of IKKβ phosphorylated at both Ser177 and Ser181. (C) Same as (A),
except that the phosphopeptides were immunoblotted with the antibody that recognizes IKKβ
phosphorylated at Ser181.
Figure S2 Effect of BI605906 on the activity of wild-type and mutant IKKβ
HA-tagged wild-type IKKβ (WT) or the IKKβ[S177E] mutant (S177E) were expressed in HEK-293
cells, immunoprecipitated from the cell extracts using an anti-HA antibody and assayed for
activity in the absence or presence of BI605906. The activities are plotted as a percentage of that
obtained in the absence of inhibitor. Results are means+−S.E.M. of duplicate determinations.
Similar results were obtained in another independent experiment.
Figure S3 BI605906 is a reversible inhibitor of IKKβ
MEFs from IKKα-deficient mice were stimulated for 10 min with 5.0 ng/ml IL-1 and the cells
were lysed. The endogenous IKKβ was immunoprecipitated from 0.2 mg of cell extract protein
and incubated for 1 h at 30◦C without ( − , lane 1) or with ( + , lanes 2 and 3) 20 μM BI605906.
In lane 3 only, the immunoprecipitates were washed extensively to remove BI605906. All the
immunoprecipitates were then assayed for IKKβ activity. The Figure shows that IKKβ activity
was full restored after washing away the inhibitor. Results are means +− S.E.M. of duplicate
determinations. Similar results were obtained in another independent experiment.
1 To whom correspondence should be addressed (email p.cohen@dundee.ac.uk).
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Figure S4 Effect of inhibitors on agonist-stimulated phosphorylation of
IKKβ at Ser177 and Ser181 in MEFs and BMDM
(A andB) MEFs from wild-type (WT) or IKKα-knockout (KO) mice were incubated for 1 h without
( − ) or with ( + ) 5.0 μM BI 605906 and then stimulated for 10 min with 5.0 ng/ml IL-1 (A) or
10 ng/ml TNF (B). Following cell lysis, cell extract (20 μg of protein) was denatured in SDS,
subjected to SDS/PAGE, and immunoblotted with antibodies that recognize IKKα and IKKβ
phosphorylated at Ser176 and Ser177 respectively, or with antibodies that recognize IKKα and
IKKβ phosphorylated at Ser180 or Ser181 respectively. The membranes were also immunoblotted
with antibodies that recognize all forms of IKKβ . (C) Same as (A and B), except that BMDMs
from wild-type (WT) mice and knockin (KI) mice expressing the catalytically inactive mutant
of IKKα were used and the cells were stimulated for 10 min with 1.0 μg/ml Pam3CSK4. An
antibody recognizing GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a
loading control.
Figure S5 Phosphorylation of MAPKs is unimpaired in MEFs from
HOIP[C879S] and NEMO[D311N] mice
(A) MEFs from wild-type mice (HOIP[WT]) or knockin mice expressing the inactive HOIP[C879S]
mutant were stimulated with 5.0 ng/ml IL-1 for the times indicated. After cell lysis, 20 μg
of cell extract protein was denatured in SDS, subjected to SDS/PAGE and immunoblotted
with the antibodies indicated. (B) Same as (A), but using MEFs from mice expressing the
polyubiquitin-binding-deficient mutant of NEMO (NEMO[D311N]). The antibody recognizing
pT183/Y185 of JNK1/2 was from Invitrogen and the antibody recognizing pT180/Y182 of p38α
MAPK was from Cell Signaling Technology.
Figure S6 TAK1 inhibitors suppress the IL-1-stimulated phosphorylation of
MAPKs in MEFs from HOIP[C879S]- and NEMO[D311N]-knockin mice
(A) As in Figure S5, except that before stimulation with IL-1, MEFs from mice expressing the
HOIP[C879S] mutant were incubated for 1 h without ( − ) or with ( + ) the TAK1 inhibitors
NG25 (1.0 μM) or 5Z-7-oxozeaenol (1.0 μM) before stimulation with 5.0 ng/ml IL-1 for the
times indicated. (B) Same as (A), except that the experiment was performed with MEFs from
mice expressing the polyubiquitin-binding-deficient mutant NEMO[D311N].
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Figure S7 Effect of TAK1 inhibition on the IL-1-stimulated formation of
Lys63-linked and Met1-linked ubiquitin chains
MEFs were incubated for 1 h with ( + ) or without ( − ) 2 μM NG25 or 1 μM 5Z-7-oxozeaenol,
then stimulated for 10 min with 5 ng/ml IL-1α and lysed. The Met1-linked and Lys63-linked
ubiquitin chains present in 2 mg of cell extract protein were captured on Halo-NEMO [1],
released by denaturation in SDS and immunoblotted with antibodies that recognize Met1-linked
or Lys63-linked ubiquitin chains specifically. The same cell extracts (20 μg of protein) were
immunoblotted with an anti-GAPDH antibody as a loading control.
Figure S8 TAK1 phosphorylates IKKβ at Ser177 and Ser181 in vitro
Catalytically inactive IKKβ[D166A] (0.8 μM) was incubated for 3 min at 30◦C with the indicated
concentrations of the active TAK1–TAB1 fusion protein in 50 mM Tris/HCl (pH 7.5), 0.1 mM
EGTA, 2 mM DTT, 10 mM magnesium acetate and 0.1 mM ATP. Reactions were terminated
by denaturation in SDS and, after SDS/PAGE and transfer on to PVDF membranes, proteins
were immunoblotted with antibodies that recognize IKKβ phosphorylated at Ser177 or Ser181 or
antibodies recognizing all forms of IKKβ .
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